Norovirus Vaccine Market Share Boosted by Advancements in Multivalent Formulations and Rising Healthcare Awareness | Valuates Reports

Norovirus Vaccine Market
The global market for Norovirus Vaccine was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

View sample report

https://reports.valuates.com/request/sample/QYRE-Auto-16E15433/Global_Norovirus_Vaccine_Market_Research_Report_2023

The Norovirus vaccine market is experiencing notable growth, driven by the increasing prevalence of norovirus infections worldwide and the urgent need for effective immunization strategies. With rising awareness of viral gastroenteritis and its significant burden on healthcare systems, vaccine development targeting multiple norovirus strains has become a key focus area.

By type, bivalent formulations currently hold a substantial market share, offering protection against two major genogroups of norovirus and serving as a critical step in early immunization efforts. Quadrivalent vaccines are gaining momentum for their expanded coverage and effectiveness across diverse norovirus strains, particularly in regions with high outbreak variability. Hexavalent formulations represent an emerging innovation in the market, aiming to deliver broader immunity and enhanced protection, especially in vulnerable populations such as children and the elderly.

In terms of application, hospitals constitute the leading end-user segment due to their role in administering vaccinations and managing outbreak containment in high-risk environments. Clinics are also key contributors to market growth, particularly in community-based immunization programs and preventive care services. The "others" category includes public health agencies, research institutions, and mobile healthcare units, which are playing an increasingly important role in vaccine distribution and awareness campaigns.

As the global healthcare sector intensifies efforts to mitigate infectious disease spread and improve population immunity, the norovirus vaccine market is expected to witness sustained market growth. Continued investment in multivalent vaccine development and broader access to immunization will remain central to market expansion and improved public health outcomes.

Segment by Type

• Bivalent
• Quadrivalent
• Hexavalent

Segment by Application

• Hospital
• Clinic
• Others

By Company

Hillevax, Vaxart, Moderna, UMN Pharma, Daiichi Sankyo, Kanghua Biology, Beijing Institute of Biological Products, Zhifei Bio, China Biotechnology Co., Ltd., North China Pharmaceutical

View full report
https://reports.valuates.com/market-reports/QYRE-Auto-16E15433/global-norovirus-vaccine

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.